Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06387342 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Namodenoson Treatment of Advanced Pancreatic Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 31, 2025 (before its estimated July 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 15, 2024 to Nov 10, 2024
    • Site details revised
    v4
  2. Start date: Jul 15, 2024 to Dec 15, 2024v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.
Trial Details
NCT Number NCT06387342
Lead Sponsor Can-Fite BioPharma
Conditions
(from sponsor)		 Pancreatic Adenocarcinoma, Pancreatic Cancer
Related terms Pancreatic Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov